Krah Simon, Schröter Christian, Eller Carla, Rhiel Laura, Rasche Nicolas, Beck Jan, Sellmann Carolin, Günther Ralf, Toleikis Lars, Hock Björn, Kolmar Harald, Becker Stefan
Institute for Organic Chemistry and Biochemistry, Technische Universität Darmstadt, Alarich-Weiss-Strasse 4, D-64287 Darmstadt, Germany.
Protein Engineering and Antibody Technologies, Merck KGaA, Frankfurter Strasse 250, D-64293 Darmstadt, Germany.
Protein Eng Des Sel. 2017 Apr 1;30(4):291-301. doi: 10.1093/protein/gzw077.
Bispecific antibodies (bsAbs) pave the way for novel therapeutic modes of action along with potential benefits in several clinical applications. However, their generation remains challenging due to the necessity of correct pairings of two different heavy and light chains and related manufacturability issues. We describe a generic approach for the generation of fully human IgG-like bsAbs. For this, heavy chain repertoires from immunized transgenic rats were combined with either a randomly chosen common light chain or a light chain of an existing therapeutic antibody and screened for binders against tumor-related targets CEACAM5 and CEACAM6 by yeast surface display. bsAbs with subnanomolar affinities were identified, wherein each separate binding arm mediated specific binding to the respective antigen. Altogether, the described strategy represents a combination of in vivo immunization with an in vitro selection method, which allows for the integration of existing therapeutic antibodies into a bispecific format.
双特异性抗体(bsAbs)为新型治疗作用模式铺平了道路,并在多种临床应用中具有潜在益处。然而,由于需要正确配对两条不同的重链和轻链以及相关的可制造性问题,其生成仍然具有挑战性。我们描述了一种生成完全人源化IgG样双特异性抗体的通用方法。为此,将免疫转基因大鼠的重链文库与随机选择的通用轻链或现有治疗性抗体的轻链相结合,并通过酵母表面展示筛选针对肿瘤相关靶点癌胚抗原相关细胞黏附分子5(CEACAM5)和癌胚抗原相关细胞黏附分子6(CEACAM6)的结合物。鉴定出具有亚纳摩尔亲和力的双特异性抗体,其中每个单独的结合臂介导与各自抗原特异性结合。总之,所描述的策略代表了体内免疫与体外选择方法的结合,这使得能够将现有的治疗性抗体整合成双特异性形式。